SGO 2024


Seagen Development Pipeline

Session Info Card

Tisotumab Vedotin | Cervical Cancer | Abstract #428204

Seeing Health Disparities in Cervical Cancer: Mapping Behavioral and Socioeconomic Drivers of Geographic Dispersion of Disease Burden with the Geo-Analyzer Tool

Tisotumab Vedotin | Cervical Cancer | Abstract #568638

Efficacy and Safety of Tisotumab Vedotin Versus Investigator’s Choice of Chemotherapy in 2L or 3L Recurrent or Metastatic Cervical Cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A Global, Randomized, Open-Label, Phase 3 Study

Tisotumab Vedotin | Cervical Cancer | Abstract #448275

Patients with advanced cervical cancer value disease control and overall survival in treatment decision-making: a US patient preference study

Disitamab Vedotin | Solid Tumors | Abstract #481945

Phase 2 Basket Study of Disitamab Vedotin in Patients With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors That Express HER2: Ovarian and Endometrial Cancer Cohorts (DV-005; Trial in Progress)